PROCEPT BioRobotics Corp (PRCT)
NasdaqGM · Price as of · Nasdaq Real Time Price
- Profitability0/20
Losing money: $-22.7M net income over the last four reported quarters. Revenue over the last four reported quarters was $337.3M, up 18% from $284.8M the year before.
- Insider buying vs selling20/20
Insiders are net buyers: 1 open-market buy worth $498,315 vs 9 sells worth $279,342 across the last 20 Form 4 filings.
- Dilution and offerings11/15
Share count up 2.9% in a year. Mild dilution.
- Analysts11
- Implied upside+3.9%
- Target range$16.00 to $28.00
- EPS expected-$0.39
- A year ago-$0.38
- Revenue expected$101.1M +21%
- Estimate range-$0.42 to -$0.34
PRCT closed at $20.60 on Aug 27, up 15.2% since Jul 29. Chart read: price above the 50-day moving average but below the 200-day; the 50-day is below the 200-day (downtrend structure); trading at 17% of the 52-week range ($16.69 to $40.68).
Insider buying and selling at PROCEPT BioRobotics Corp (PRCT)
The most recent Form 4 on record for PROCEPT BioRobotics Corp (PRCT) is August 7, 2026, when Larry L Wood, President, CEO, bought $498,315 of stock. An open-market purchase is money the filer chose to put in.
| Insider | Action | Value | Date | Type |
|---|---|---|---|---|
| Larry L Wood · President, CEO | Buy | $498,315 | August 7, 2026 | Own call |
| Antal Rohit Desai · Director | Buy | $10.5M | March 5, 2026 | Own call |
| Frederic H Moll · Director | Buy | $785,138 | August 13, 2025 | Own call |
SEC filings
| Form | Filed | Description |
|---|---|---|
| 4 | August 14, 2026 | FORM 4 |
| 4 | August 14, 2026 | FORM 4 |
| 4 | August 14, 2026 | FORM 4 |
| 4 | August 14, 2026 | FORM 4 |
| 4 | August 10, 2026 | FORM 4 |
| 10-Q | August 5, 2026 | 10-Q |
| 8-K | August 4, 2026 | 8-K |
| SCHEDULE 13G/A | July 29, 2026 | View on EDGAR |
Articles that mention PROCEPT BioRobotics without it being the main subject.
All seven Magnificent Seven stocks fell today. Here's where that money actually went (July 23, 2026)
All seven Magnificent Seven stocks were red by late morning Thursday, led by Tesla's 14% drop on an earnings miss and Alphabet's close-to-7% slide despite beating estimates, on another capex raise. Amazon and Meta sold off too ahead of next week's reports. The money didn't just leave, it rotated: into defense on Lockheed's earnings beat, and out of quantum, SaaS and space.
The Close, July 14: IBM lost a quarter of its value, and SK Hynix's Nasdaq stock jumped 27%
IBM lost about a quarter of its value in a single session after a weak preliminary report, and the damage spread across enterprise software. SK Hynix's brand-new Nasdaq stock went the other way, jumping 27% on a day chips broadly rallied.
Frequently asked questions
When does PRCT report earnings?
PROCEPT BioRobotics Corp (PRCT) is scheduled to report quarterly results on November 4, 2026. The 10-analyst consensus is -$0.39 per share on revenue of $101.1M for the quarter ending September 30, 2026, against -$0.38 and $83.3M a year earlier. It has beaten the consensus EPS estimate in 2 of the last four quarters.
What do analysts expect for PRCT?
11 analysts cover PROCEPT BioRobotics Corp (PRCT). The consensus rating is Hold. The average price target is $21.64, in a range of $16.00 to $28.00.
Are insiders buying or selling PRCT?
We track Form 4 filings for PROCEPT BioRobotics Corp (PRCT). The activity listed on this page shows 3 open-market purchases. Each row is labelled Routine when the filer declared a pre-arranged 10b5-1 plan, Tax withholding when shares were sold automatically to cover the tax on a vest, or Own call when neither applies.
Where can I see PRCT SEC filings?
Recent filings are listed on this page, newest first. The latest is a 4 filed August 14, 2026.